Premium
Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement
Author(s) -
delaFuente Cristina,
Nuñez Fidel,
CortésRomera Montserrat,
FranchSarto Mireia,
Ribera JosepMaria,
Sancho JuanManuel
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2836
Subject(s) - pembrolizumab , lymphoma , medicine , central nervous system , refractory (planetary science) , primary central nervous system lymphoma , cancer research , antibody , monoclonal antibody , immune system , monoclonal , immunotherapy , immunology , biology , astrobiology
Primary mediastinal large B‐cell lymphoma (PMBCL) is a rare aggressive B‐cell lymphoma characterized by the frequent presence of amplification and translocation events at 9p24.1, resulting in the expression of the programmed cell death‐1 (PD‐1) ligands PD‐L1 and PD‐L2. Pembrolizumab, a humanized anti‐PD‐1 monoclonal antibody, binds PD‐1 and blocks this interaction, enhancing the activity of the immune system against tumor cells, and has shown activity in PMBCL and in some cases of primary and secondary central nervous system (CNS) lymphoma. We report the case of a 40‐year‐old woman diagnosed with relapsed PMBCL and secondary CNS involvement who responded to pembrolizumab monotherapy, allowing for a later allogeneic stem cell transplant.